PDS Wins 2018 DIGI Award for Best Deployment, Entertainment

The movies recently got a little more magical—and as a result, the motion picture industry stands poised to ride the wave of the next phase in the movie-going revolution. Each upgrade in the history of cinema can be correlated to the display device, the actual screen holding audiences around the world captive in a director’s unique movie vision. The first era of cinema was based on 35MM film projection, and then 70MM for increased quality and differentiation. The second era in the movies was the adoption of digital cinema, starting with 2K and moving to 4K.

The third era in Cinema is dawning right now.

Introduced by Samsung at CinemaCon 2017, direct view LED showcases film in high definition using bright and vibrant color. With an array measuring 40 feet and using 96 LED cabinets attached to a custom engineered visual structure, this switch from film projector technology is a giant leap forward in film that absolutely stunned conference viewers.

Direct view LED exceeds current DCI standards for visual quality. In fact, Samsung demonstrated ten times the brightness compared to standard digital cinema. Theater owners integrating direct view LED can also enjoy 100,000 hours (up to 15 years) of service life.

PDS Wins 2018 DIGI Award for Best Deployment, Entertainment

Engineering this project for the very first LED cinema mobile and temporary installation required close coordination with the Samsung team and venue staff. There was zero room for error, and the schedule was set in stone for the CinemaCon Show held at The Orleans Hotel & Casino in Las Vegas.

Recognizing the significance of the project to the entire motion picture industry, PDS brought their successful track record of taking responsibility for projects of this scale to fruition. PDS provided needs analysis, engineering, scaled dimensional drawings, manufacturing, on-site consultation, installation, and final testing to bring direct-lit LED technology for High Dynamic Range (HDR) to the Cinemark Century Orleans 18 and XD Theatre.

Presented by Digital Signage Magazine in recognition of the special challenges of this project, PDS won the 2018 DIGI Award, for Best Deployment, Entertainment–Temporary Installation. “From fine-pitch LED in unusual entertainment applications to merchandising at the highest levels to employee-facing systems for corporations, the DIGI Awards are still the best look at how digital signage and DOOH best practices are defining a new digital landscape,” says Chair of the Judges Committee for the DIGI Awards, NewBay Media executive editor David Keene.

The entire PDS team is pleased to accept the coveted 2018 DIGI award.

To learn more about Premier Dedicated Solutions, visit pdscustom.com/services/design-and-engineering/today.

Read more at http://pdscustom.com

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More